Jermasek Douglas
Known title: EVP of Corporate StrategyCIK: 0001955273
Associated companies
Transaction History
| UNCY | ▲ Buy | Option Exercise | 104,612 | — | 7/11/2023 | View on chart |
| UNCY | ▲ Buy | Option Exercise | 104,612 | — | 7/11/2023 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Unicycive Resubmits FDA Application Amid Securities Lawsuit
Unicycive Therapeutics has resubmitted its FDA application for oxylanthanum carbonate, targeting a PDUFA date six months from now. This regulatory update comes alongside a securities class action filed in September, alleging violations related to previous statements about the drug application. The stock is currently trading near its 52-week low, reflecting the combined weight of legal and regulatory developments.
Unicycive Resubmits FDA Application Amid Securities Lawsuit. Unicycive Therapeutics has resubmitted its FDA application for oxylanthanum carbonate, targeting a PDUFA date six months from now. This regulatory update comes alongside a securities class action filed in September, alleging violations related to previous statements about the drug application. The stock is currently trading near its 52-week low, reflecting the combined weight of legal and regulatory developments.